FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of pharmaceutics and medicine, namely to methods of preventing, treating, relieving or controlling pancreatitis in a subject in need thereof, wherein the subject has an elevated level of CA19-9 in the pancreatic flow area, comprising administering to the subject an antibody which binds to sialyl-Lewisa.
EFFECT: preventing, treating, relieving or controlling pancreatitis in a subject having an elevated level of CA19-9 in a pancreatic duct.
33 cl, 67 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS | 2014 |
|
RU2699289C2 |
| NUCLEIC ACIDS ENCODING ANTIBODIES AGAINST SIALYLATED HUMAN LEWIS ANTIGEN | 2014 |
|
RU2791967C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| NEW ANTI-CD19 ANTIBODIES | 2018 |
|
RU2791445C2 |
| ANTIBODIES TO FACTOR XI | 2017 |
|
RU2800719C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| IL-4/IL-13 PATHWAY INHIBITORS FOR HIGHER EFFICACY IN TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2836467C2 |
